Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Lilly Japan Chief Sees Continued Diabetes Investment as Key to Remaining in Top 10
June 22, 2020
- Shionogi Preparing Commercial Production of COVID-19 Vaccine Simultaneously with Development
June 22, 2020
- Sawai to Halt Erythromycin Shipment by July End due to Deviations from Specifications
June 22, 2020
- Oncolys Strikes Deal with Kagoshima Univ. to Develop COVID-19 Therapy
June 22, 2020
- Urovant, Sunovion Ink Distribution Pact for OAB Med Vibegron; Both Sumitomo Dainippon Units
June 22, 2020
- Pfizer Launches Celecox Authorized Generic, Its 1st AG
June 22, 2020
- Crysvita Approved for Tumor-Induced Osteomalacia in US: Kyowa Kirin/Ultragenyx
June 22, 2020
- Keytruda Logs 64% Growth, Tops FY2019 Drug Ranking: Jiho Tally
June 19, 2020
- 5 Authorized Generics Hit Japan Market on June 19
June 19, 2020
- Ono President Confident of Validity of Company’s Argument on Opdivo Royalties
June 19, 2020
- AZ Recalls Omepral Injection in Japan due to Flaws in Environmental Monitoring Data
June 19, 2020
- NanoCarrier’s NC-6004 Hits Goal in Keytruda Combo for Head and Neck Cancer
June 19, 2020
- Lilly’s Ultra-Fast Acting Insulin Lyumjev Now Available in Japan
June 18, 2020
- Kyowa Kirin Commits Up to US$10 Million in 4BIO Venture Fund, Its 1st VC Investment
June 18, 2020
- Takeda Out-Licenses 7 Psych Programs to Neurocrine
June 18, 2020
- Canada OKs Sunovion’s Apomorphine Sublingual Film for Parkinson’s
June 17, 2020
- 10 Foreign Makers in Japan Grow Above Market with 5.5% Sales Rise in 2019
June 17, 2020
- Distributors See 800 Item Shortages as Good Guesstimate as They Share Off-Year Survey Concerns with Chuikyo Wholesaler Rep
June 17, 2020
- Astellas Relaxes Commuting Rate Limit to 50% at HQ as COVID-19 Situation Improves
June 17, 2020
- Oncolys Inks US$300 Million-Plus Pact for OBP-601; Potential for Neurodegenerative Diseases Eyed
June 16, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…